EPITOPEA APS NUF

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based cancer vaccines targeting aberrantly expressed tumour-specific antigens (aeTSAs) hidden in 'junk DNA'. Their proprietary CryptoMap™ platform identifies shared Cryptigen™ TSAs across patients with the same tumour type, enabling next-generation immunotherapies for difficult-to-treat cancers. The company is accelerating toward clinical-stage development with a growing scientific advisory board of cancer immunology experts.